MEBO Group Partners with Xiamen Haicang Biopharmaceutical Port to Drive Global Expansion

On September 23, MEBO Group President Yang Zhibin, together with senior executives, attended a strategic signing ceremony in Xiamen with Xiamen Haicang Biotech Development Co., Ltd., the operating company of Haicang Biopharmaceutical Port. General Manager Li Ye and representatives of more than ten pharmaceutical enterprises in the park joined the event to witness the launch of the partnership.

With over 30 years of expertise in medical innovation, MEBO Group has grown from pioneering regenerative therapies to building global market networks. Xiamen Haicang Biopharmaceutical Port, as one of China’s leading biotech clusters, integrates R&D, manufacturing, and distribution, and hosts a wide range of enterprises seeking international growth.

The partnership combines the Port’s cluster resources with MEBO’s global market experience and regulatory expertise to offer “one-stop” solutions for overseas expansion, including compliance consulting, international certification, and market access.

Both sides emphasized their commitment to helping “Made in Xiamen” biopharmaceutical products enter global markets, contributing to the internationalization of China’s biotech industry.

About MEBO

Founded in 1987 by Professor Rongxiang Xu, a distinguished Chinese life scientist, MEBO Group is a multinational headquartered in both China and the USA. It integrates research, development, and sales across the pharmaceuticals, medical devices, health foods, and cosmetics sectors.

At its core, MEBO focuses on regenerative life sciences, innovating with over 100 patents and more than ten joint research bases to enhance and enable the body's own regenerative abilities.

As a leader in regenerative life science, MEBO's extensive research facilities and products impact over 100 countries globally, pioneering new frontiers in the regenerative life world.